Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2005 1
2007 1
2008 1
2012 3
2013 1
2014 6
2015 3
2016 2
2018 3
2019 4
2021 5
2022 6
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). Lalla RV, et al. Cancer. 2014 May 15;120(10):1453-61. doi: 10.1002/cncr.28592. Epub 2014 Feb 25. Cancer. 2014. PMID: 24615748 Free PMC article. Review.
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.
Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Barberio B, et al. J Crohns Colitis. 2021 Jul 5;15(7):1184-1196. doi: 10.1093/ecco-jcc/jjab010. J Crohns Colitis. 2021. PMID: 33433562 Free article.
Combined therapy ranked first in trials where 50% of patients had left-sided/extensive disease, and topical mesalazine first in trials where 50% of patients had proctitis/proctosigmoiditis. High-dose [3.3 g/day] oral mesalazine ranked third in most analyses, with the most …
Combined therapy ranked first in trials where 50% of patients had left-sided/extensive disease, and topical mesalazine first in trials where …
Systematic review of therapies for refractory ulcerative proctitis.
Raja SS, Bryant RV, Costello SP, Barnett M, Schubert J, Rayner CK. Raja SS, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):496-509. doi: 10.1111/jgh.16111. Epub 2023 Feb 6. J Gastroenterol Hepatol. 2023. PMID: 36644922 Review.
Patients with ulcerative proctitis have favorable long-term outcomes but are typically excluded from ulcerative colitis clinical trials. Refractory proctitis presents a management conundrum for gastroenterologists, and there remains a lack of clarity as to the best …
Patients with ulcerative proctitis have favorable long-term outcomes but are typically excluded from ulcerative colitis clinical tria …
Drug therapies for ulcerative proctitis: systematic review and meta-analysis.
Lie MR, Kanis SL, Hansen BE, van der Woude CJ. Lie MR, et al. Inflamm Bowel Dis. 2014 Nov;20(11):2157-78. doi: 10.1097/MIB.0000000000000141. Inflamm Bowel Dis. 2014. PMID: 25072502 Review.
BACKGROUND: Patients with ulcerative colitis limited to the proctum are considered to have ulcerative proctitis (UP). In patients with more extensive ulcerative colitis, treatment occurs in a step-up fashion (5-ASA, corticosteroids, thiopurines, anti-TNF-alpha agents), a s …
BACKGROUND: Patients with ulcerative colitis limited to the proctum are considered to have ulcerative proctitis (UP). In patients wit …
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Aruljothy A, Singh S, Narula N, Moran GW, Vuyyuru SK, Hogan M, Zayadi A, MacDonald JK, Caron B, Danese S, Peyrin Biroulet L, Ma C, Jairath V. Aruljothy A, et al. Aliment Pharmacol Ther. 2023 Oct;58(8):740-762. doi: 10.1111/apt.17666. Epub 2023 Aug 17. Aliment Pharmacol Ther. 2023. PMID: 37589498 Review.
BACKGROUND: Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat. ...
BACKGROUND: Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat. ...
Diagnosis and Management of Cuffitis: A Systematic Review.
Hembree AE, Scherl E. Hembree AE, et al. Dis Colon Rectum. 2022 Dec 1;65(S1):S85-S91. doi: 10.1097/DCR.0000000000002593. Epub 2022 Aug 25. Dis Colon Rectum. 2022. PMID: 36399769
This review found that the majority of the current literature fails to distinguish between classic cuffitis (a form of reminant ulcerative proctitis) and nonclassic cuffitis (resulting from other causes). Further work is needed to distinguish the unique risk factors and en …
This review found that the majority of the current literature fails to distinguish between classic cuffitis (a form of reminant ulcerative …
Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review.
Salem G, Ding K, Sakuraba A, Cohen R. Salem G, et al. J Investig Med. 2021 Feb 23:jim-2020-001699. doi: 10.1136/jim-2020-001699. Online ahead of print. J Investig Med. 2021. PMID: 33622709 Review.
Study subjects were categorized into three groups: topical tacrolimus for patients with proctitis, perianal CD, and chronic refractory pouchitis. The primary end point of this study was the remission rate. ...Clinical remission was achieved in 57.1%, 57.14%, and 70.0% in p …
Study subjects were categorized into three groups: topical tacrolimus for patients with proctitis, perianal CD, and chronic refractor …
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Caron B, et al. J Crohns Colitis. 2022 Jul 14;16(6):922-930. doi: 10.1093/ecco-jcc/jjab218. J Crohns Colitis. 2022. PMID: 34850857
BACKGROUND: Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease. ...One observational study suggested azathioprine may be effective in patients with ulcerative proctitis. Only two cohort studies evaluated the efficacy of …
BACKGROUND: Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease. ...One observational st …
Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis.
De Silva TA, Alphonsus L, Ma C, Hogan M, Sedano R, Narula N, Danese S, Peyrin-Biroulet L, MacDonald JK, Singh S, Jairath V. De Silva TA, et al. J Crohns Colitis. 2023 Jan 27;17(1):123-136. doi: 10.1093/ecco-jcc/jjac109. J Crohns Colitis. 2023. PMID: 35930405
BACKGROUND AND AIMS: Treatment options for proctitis are limited. To assist trial design for novel therapeutics, we conducted a systematic review and meta-analysis of proctitis randomized controlled trials [RCTs] to quantify placebo rates and identify factors influe …
BACKGROUND AND AIMS: Treatment options for proctitis are limited. To assist trial design for novel therapeutics, we conducted a syste …
Demographic, Epidemiologic, and Clinical Characteristics of Human Monkeypox Disease Pre- and Post-2022 Outbreaks: A Systematic Review and Meta-Analysis.
Hatami H, Jamshidi P, Arbabi M, Safavi-Naini SAA, Farokh P, Izadi-Jorshari G, Mohammadzadeh B, Nasiri MJ, Zandi M, Nayebzade A, Sechi LA. Hatami H, et al. Biomedicines. 2023 Mar 20;11(3):957. doi: 10.3390/biomedicines11030957. Biomedicines. 2023. PMID: 36979936 Free PMC article. Review.
The most common clinical manifestations were rash, fever, lymphadenopathy, and malaise/fatigue. Proctalgia/proctitis (16.6%, 95% CI 10.3-25.6, I(2): 97.76) and anal/perianal lesions (39.8%, 95% CI 30.4-49.9, I(2): 98.10) were the unprecedented clinical manifestations durin …
The most common clinical manifestations were rash, fever, lymphadenopathy, and malaise/fatigue. Proctalgia/proctitis (16.6%, 95% CI 1 …
53 results